Bevacizumab (Avastin) for colorectal cancer
Record ID 32008000008
English
Authors' objectives:
Bevacizumab (Avastin; Genentech Inc.) is a humanized monoclonal antibody that binds to and inhibits the biologic activity of the vascular endothelial growth factor. It is used in combination with intravenous 5-fluorouracil-based chemotherapy as a first-line treatment and as an adjunct to chemotherapy for the second-line treatment of patients with metastatic colorectal cancer.
Authors' methods:
Review
Details
Project Status:
Completed
Year Published:
2007
URL for published report:
http://www.hayesinc.com/hayes/crd/?crd=6658
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Antibodies, Monoclonal
- Colorectal Neoplasms
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
HAYES, Inc.
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.